DNA
NYSEGINKGO BIOWORKS HOLDINGS, INC.
Basic Materials · Biological Products, (No Diagnostic Substances)
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$313.8M
2021
$477.7M
2022
$251.5M
2023
$227.0M
2024
$170.2M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$170.2M
Net Income$-312.8M
Gross Profit—
Oper Income$-315.3M
EPS (dil)$-5.64
Rev/sh—
FCF/sh—
Book/sh—
Gross M—
Oper M-185.3%
Profit M-183.8%
FCF M-105.0%
ROE-61.5%
ROA-27.9%
ROIC-106.1%
R&D/Rev143.3%
Rev Y/Y-25.1%
Rev 3Y CAGR-29.1%
EPS Y/Y46.5%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+6.9%
Current Ratio4.92
Quick Ratio4.92
Debt/Eq—
Int Coverage—
Net Debt—
Total Debt—
Cash & Eq$212.4M
Total Assets$1.1B
Oper CF$-171.1M
Capex$7.7M
Free CF$-178.7M
Buybacks$408,000
Equity$508.6M
Liabilities$611.1M
Shs Outstand—
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $313.8M | $477.7M | $251.5M | $227.0M | $170.2M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-1.8B | $-2.2B | $-864.4M | $-559.8M | $-315.3M |
| Net Income | $-1.8B | $-2.1B | $-892.9M | $-547.0M | $-312.8M |
| Diluted EPS | $-1.39 | $-50.20 | $-18.37 | $-10.54 | $-5.64 |
| Operating Cash Flow | $-253.8M | $-252.2M | $-295.5M | $-319.6M | $-171.1M |
| Free Cash Flow | $-310.3M | $-304.5M | $-336.3M | $-382.1M | $-178.7M |
COMMUNITY · $DNA0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.